<DOC>
	<DOCNO>NCT01457937</DOCNO>
	<brief_summary>The cohort post-menopausal woman represent group very-difficult-to-treat patient powerful approach require order improve disappointing response rate . Thus addition , patient previous failure PEG/RBV treatment naïve patient , powerful drug like Boceprevir could greatly improve SVR rate suggest result SPRINT_2 trial Boceprevir addition determine 30 % improvement SVR rate difficult gt 1 patient African descent versus standard PEG IFN/Ribavirin therapy RESPOND-2 show percent improvement RGT-retreatment Boc/P/R previous failure standard therapy . Goal study verify whether addition 24-week treatment boceprevir standard antiviral therapy Peg IFN ribavirin increase rate SVR patient difficult treat , HCV-positive woman post-menopausal woman genotype 1 , never treat , also respond previous treatment peginterferon ribavirin ( Riba ) .</brief_summary>
	<brief_title>Boceprevir/PegIFN α-2b/Riba HCV+ Gt1 Menopausal Women , Nonresponders PegIFN/Riba Treatment-naives ( MEN_BOC )</brief_title>
	<detailed_description>2.2.1 Hypothesis Our hypothesis addition 24-week treatment boceprevir standard antiviral therapy Peg IFN ribavirin increase rate sustain virological response ( SVR ) patient difficult treat , HCV-positive woman post-menopausal woman genotype 1 , never treat , also respond previous treatment peginterferon ribavirin ( Riba ) Objectives Retreatment Primary objective Verify whether sustained virological response ( SVR define HCV RNA undetectable 24 week follow-up ) menopausal woman HCV CAH genotype 1 achieve sustained virological response previous treatment PEG IFN/ribavirin may increase least 20 % treatment PEG IFN alfa 2b boceprevir ( 1.5 mcg / kg QW ) + Ribavirin ( 800-1400 mg / day ) The primary efficacy endpoint , achieve SVR , evaluate descriptive statistic ( n , % ) treatment arm . Secondary objective It represent evaluation percent patient early virological response ( undetectable HCV RNA week 2 , 4 , 8 12 ) reach SVR . Naïve patient Primary objective Verify whether SVR , define undetectable HCV-RNA 24 week follow-up may increase least 25 % treatment PEG IFN alfa 2b plus ribavirin boceprevir vs. PEG IFN alfa 2b plus ribavirin alone , postmenopausal woman CHC genotype 1 previously treat The primary efficacy endpoint , achieve SVR , evaluate descriptive statistic ( n , % ) treatment arm . Secondary objective It represent evaluation percent patient early virological response ( undetectable HCV RNA week 2 , 4 , 8 12 ) reach SVR .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Menopausal females previously document CHC infection , either ( A ) relapser &gt; 2log10 IU/ml HCV RNA decrease week 12 previous PEG IFN/Ribavirin treatment ( B ) naives ; Subject must liver biopsy within last 2 year histology consistent CHC etiology . Subjects bridge fibrosis cirrhosis must ultrasound within 6 month Screening Visit ( Screening Day 1 ) finding suspicious hepatocellular carcinoma ( HCC ) . Subject must willing give write informed consent . Coinfection human immunodeficiency virus ( HIV ) hepatitis B virus ( HBsAg positive ) . Treatment investigational drug within 30 day randomization visit study . Participation clinical trial within 30 day randomization intention participate another clinical trial participation study . Evidence decompensated liver disease include , limited , history presence clinical ascites , bleed varix , hepatic encephalopathy . Diabetic and/or hypertensive subject clinically significant ocular examination finding : retinopathy , cotton wool spot , optic nerve disorder , retinal hemorrhage , clinically significant abnormality . Preexisting psychiatric condition ( ) . Clinical diagnosis substance abuse specify drug within specify timeframes . Any known preexisting medical condition could interfere subject 's participation completion study . Evidence active suspect malignancy , history malignancy , within last 5 year ( except adequately treat carcinoma situ basal cell carcinoma skin ) . Subjects evaluation malignancy eligible . Subjects lifethreatening serious adverse event ( SAE ) screen period . Protocolspecified hematologic , biochemical , serologic criterion : Hemoglobin &lt; 12 g/dL female &lt; 13 g/dL male ; Neutrophils &lt; 1500/mm^3 ( black : &lt; 1200/mm^3 ) ; Platelets &lt; 100,000/mm^3 ; Direct bilirubin &gt; 1.5 x upper limit normal ( ULN ) Serum albumin &lt; low limit normal ( LLN ) Thyroidstimulating hormone ( TSH ) &gt; 1.2 x ULN &lt; 0.8 x LLN laboratory , certain exception . Serum creatinine &gt; ULN laboratory reference . Protocolspecified serum glucose concentration . Prothrombin time/partial thromboplastin time ( PT/PTT ) value &gt; 10 % laboratory reference range . Antinuclear antibody ( ANA ) &gt; 1:320 .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>HCV</keyword>
	<keyword>Menopause</keyword>
	<keyword>Peg IFN</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Boceprevir</keyword>
</DOC>